West Boca Medical Center Opens New Interventional Vascular Imaging Suite

West Boca Medical Center increases its services in the community by offering patients advanced vascular and interventional imaging procedures in its new imaging suite and interventional radiology lab.

The new lab will add the Siemens Artis Q system to enhance imaging and invasive services. The system features high-resolution capabilities, which enhance minimally invasive therapies for peripheral vascular disease, embolization, and diagnostic examination.

“We are excited to bring this enhanced level of interventional and vascular capabilities to our patients that can be accessed right here in their community,” said George Rizzuto, chief executive officer of West Boca Medical Center.  “Our first priority is to deliver the highest quality and safest treatments to our patients.  These services and this new lab demonstrates our commitment by continuing to bring the most current technology and resources to Palm Beach County.”

Some of the benefits of this new technology include:

  • Superior image quality that provides better visualization of small vessels, devices, and tissue.
  • Enhanced system efficiency to produce the highest image quality at the lowest possible doses.
  • Improved interventional imaging for treatment of peripheral vascular disease.
  • Ability to perform rotational imaging for 3D reconstruction and vascular road mapping.
  • Integration of other imaging modalities, including CT and ultrasound, that provides a basis for planning therapies, such as embolization of tumors.

This $4 million dollar investment will allow West Boca Medical Center to partner with sister hospital Delray Medical Center to expand its vascular services and offer patients this specialized care and technology in the community.  For more information go to www.westbocamedctr.com or call 561-488-8000.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”